Category

Monoclonal Antibodies Market Size, Share, Opportunities, And Trends By Indication (Inflammatory Disease, Cancer, Microbial Disease, Others), By Source (Humanized, Human, Chimeric, Murine), By Application (Diagnostic, Therapeutic, Others), By End-User (Hospitals & Clinics, Research Laboratories) And By Geography - Forecasts From 2019 To 2024.

114 pages
Published on : May 2019
Report Code : KSI061610595

Description

The monoclonal antibodies market is projected to grow at a CAGR of 6.34% to reach US$131.766 billion by 2023, from US$91.122 billion in 2017. Monoclonal is a class of antibodies with identical offspring of a hybridoma, derived by cell division from a single ancestral cell. The market for monoclonal antibodies is driven by persistent innovation in drug development and discovery, increasing incidences of chronic diseases, favorable regulatory policies, and high adoption rate of therapeutic antibodies in emerging economies.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top-down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the monoclonal antibodies value chain. The last step involves complete market engineering which includes analyzing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the monoclonal antibodies market.

Major industry players profiled as part of the report are Merck & Co. Inc., Novartis AG, Abbot, and Johnson & Johnson Services, Inc. among others.

Segmentation

The monoclonal antibodies market has been analyzed through the following segments:

By Indication

Inflammatory Disease

Cancer

Microbial Disease

Others


By Source

Humanized

Human

Chimeric

Murine


By Application

Diagnostic

Therapeutic

Others


By End-User

Hospitals & Clinics

Research Laboratories


By Geography

North America

USA

Canada

Mexico

Others


South America

Brazil

Argentina

Others


Europe

Germany

France

United Kingdom

Others


Middle East and Africa

Saudi Arabia

Israel

Others


Asia Pacific

China

Japan

South Korea

India

Others

OUR CLIENTS